Enrich rare circulating tumor cells from whole blood then isolate and retrieve a single cell.

Celsee Diagnostics, an innovator in microfluidic rare-cell isolation, characterization and retrieval platforms announced today the receipt of two additional US patents for their cell capture technologies.

U.S. Patent No. 9746413B2, “Cell Capture System and Method of Use”, and U.S. Patent No. 9752181B2 “System and Method for Capturing and Analyzing Cells” apply to the core technology of Celsee’s rare cell enrichment from blood followed by specific single cell isolation or multiplexed single cell genomic analysis. Some of these enabling technologies are embedded in Celsee PREP microfluidic chip and Celsee PREP SingleCell nanowell chip technologies. The two technologies can be used individually or used together in a combined workflow to enrich circulating tumor cells from whole blood and then isolate and retrieve a single cell. Alternatively, a vast array of cells can be isolated from heterogeneous cell suspensions with the SingleCell chip for multi-omics analyses, including single cell genomics.

“Efficient cell capture technologies with flexible analysis options and a robust retrieval system are crucial to spark the next wave of discovery and utility in precision biology. Our growing intellectual portfolio allows us the opportunity to continue to expand our automated platforms with numerous applications, especially in Single Cell Genomics,” said Celsee Diagnostics’ President and Chief Executive Officer Kalyan Handique.

About Celsee Diagnostics
Celsee Diagnostics, a privately-held company, develops, manufactures, and markets innovative, integrated microfluidic systems for rare- and single-cell isolation, analysis, and enumeration for Oncology/Immuno-Oncology life science and clinical research applications. The label-free Celsee PREP100 and PREP400 platforms perform all the required processing steps to isolate and execute single-cell analysis including immunochemistry, DNA FISH and mRNA FISH, while the Celsee ANALYZER scans and analyzes the prepared microfluidic chip automatically. The Celsee PREP SingleCell platform integrates isolation, staining and retrieval providing an unprecedented yield, almost 100%, of viable cells for culture, PCR or NGS at a cost of one-tenth that of competitive systems. Platforms can be used alone or in tandem in a streamlined workflow.